Call for Abstract
This page is for overseas participants only.
Participants who live in Japan, including the foreign students, should submit abstracts from the abstract submission page in Japanese.
Abstract Submission guidelines
（The 68th Annual Meeting of the Japanese Society of Pediatric Hematology / Oncology）
1. Abstract Submission
April 1 (Wed), 2026 – May 20 (Wed), 2026, 12:00 PM (JST)
2. Application for Abstract
(Paper Presentation/Poster Presentation)
Select the style of presentation, either Paper presentation or Poster presentation.
Select an appropriate category from the following list.
| 001 | ALL | 019 | Miscellaneous Solid Tumors |
|---|---|---|---|
| 002 | AML | 020 | Diagnostic Imaging |
| 003 | Lymphoma | 021 | Hematopoietic Cell Transplantation |
| 004 | Myeloproliferative Disorder | 022 | Surgery |
| 005 | MDS/JMML | 023 | Radiotherapy |
| 006 | Aplastic Anemia | 024 | Novel Approach |
| 007 | Thrombosis and Hemostasis | 025 | Supportive Care |
| 008 | Platelet | 026 | Late Effect |
| 009 | HLH/LCH | 027 | Palliative Care |
| 010 | Miscellaneous Hematological Disorders |
028 | Support for children and their family |
| 011 | Brain Tumor | 029 | Epidemiology/Biostatistics |
| 012 | Neuroblastoma | 030 | International Cooperation |
| 013 | Renal Tumor | 031 | Immune Disorder |
| 014 | Liver Tumor | 032 | Pathology |
| 015 | Ewing Sarcoma | 033 | Basic Research for Solid Tumors |
| 016 | Rhabdomyosarcoma | 034 | Vascular Malformation |
| 017 | Osteosarcoma | 035 | Survivorship |
| 018 | Germ Cell Tumor | 036 | Miscellaneous |
3. Submission Guidelines
| Language | English |
|---|---|
| Abstract Title | 20 words including spaces |
| Abstract Body N | No longer than 1,600 characters, including spaces (This roughly corresponds to 300–350 words) |
| No. of authors | Maximum 15 persons (including first author and co-authors) |
- Online registration is required before the congress date.
- All the submitted abstracts will be equally evaluated by peer-reviewed by the program committee. Please note that the decision on abstract acceptance/rejection is left to the sole discretion of the Congress President.
- Notification of acceptance/rejection of your abstract will be sent to the registered e-mail by the evening on 31 on August, 2026.
- All the accepted English abstracts will be published in Pediatric Blood & Cancer.
4. Conflict of Interest (COI)
- The presenting author is required to report applicable COI of not only the presenting author, but also all co-authors. Please refer to the JSPHO website for details.
▶Conflict of Interest Policies in Medical Research in Pediatric Hematology / Oncology Field
▶Detailed Regulations Concerning the Handling of Conflict of Interest - The first author who is required to declare a conflict of interest should register COI disclosure at the time of abstract submission.
- For Paper Presentation, all speakers must disclose their COI status of the past 3 years on the second slide of your presentation slide.
SAMPLE (For Paper Presentation)
- For Poster Presentation, all presenters must disclose their COI status of the past 3 years at the end of the poster presentation.
SAMPLE (For Poster Presentation)
5. Abstract Submission
- All abstracts should be submitted by email. (Email: endai-jspho2026@convention.co.jp)
- Title of the Email should include “Abstract Submission_(Your Name)”.
- Please download and attach the following files in your email.
6. Inquiries
Congress Secretariat of
The 68th Annual Meeting of The Japanese Society of Pediatric Hematology / Oncology
The 24th Annual Meeting of the Japanese Society of Pediatric Oncology Nursing
The 31st Open Symposium of the Childrenʼs Cancer Association of Japan
c/o Japan Convention Services, Inc.
14F Daido Seimei Kasumigaseki Bldg.
1-4-2, Kasumigaseki, Chiyoda-ku,
Tokyo 100-0013, Japan
E-mail: endai-jspho2026@convention.co.jp